T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. The company’s technology has been validated in multiple published scientific papers, and proven to work with viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The Company is developing a pipeline of diagnostic products based on its technology, including devices for hospitals, diagnostic laboratories and medical offices, as well as individual patients. T2 Biosystems was founded in 2006 by renowned researchers including Robert Langer, PhD, Michael Cima, PhD and Tyler Jacks, PhD from the Massachusetts Institute of Technology, and Ralph Weissleder, MD and PhD and Lee Josephson, PhD from Massachusetts General Hospital. The company has assembled a world-class team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs. T2 Biosystems is located in Cambridge, Massachusetts. T2 Biosystems' technology has been proven effective in laboratories of T2 Biosystems and the T2 Biosystems founders. It will be available to hospitals, diagnostic laboratories and medical offices in two to three years. Longer term, T2 will offer miniaturized wearable or handheld versions of the technology, which will allow individual consumers to continuously monitor their own health conditions. The technology is positioned to become the dominant diagnostic platform of the future.